Study guide

2.2 Advanced Life Support (ALS): Emergency Pharmacopeia, Reversals & Defibrillation

Veterinary Technician Specialist in Emergency and Critical Care VTS ECC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Triage & Point-of-Care Assessment

1.1 AVECCTN Examination Structure, Blueprint & Credentialing 1.2 Emergency Triage Systems, Primary Survey & Capsule Diagnostics 1.3 Point-of-Care Ultrasound (POCUS / TFAST / AFAST / VetBLUE) & Rapid Interventions

2 Chapter 2: Cardiovascular Emergencies & RECOVER CPR

2.1 RECOVER Guidelines: Basic Life Support (BLS) & Resuscitation Dynamics 2.2 Advanced Life Support (ALS): Emergency Pharmacopeia, Reversals & Defibrillation 2.3 Electrocardiogram (ECG) Interpretation & Antiarrhythmic Therapy 2.4 Congestive Heart Failure, Cardiac Tamponade & Feline Aortic Thromboembolism

3 Chapter 3: Fluid Therapy, Shock Resuscitation & Acid-Base Balance

3.1 Pathophysiology, Stages & Classification of Shock 3.2 Fluid Dynamics, Crystalloids, Colloids & Hypertonic Resuscitation 3.3 Electrolyte Disorders: Potassium, Sodium, Calcium & Phosphorus 3.4 Arterial & Venous Blood Gas Analysis & Acid-Base Disorders

4 Chapter 4: Respiratory Emergencies & Mechanical Ventilation

4.1 Upper Airway Obstruction: BOAS, Laryngeal Paralysis & Tracheal Collapse 4.2 Lower Airway, Pulmonary Parenchymal & Vascular Emergencies: Asthma, Contusions & ARDS 4.3 Pleural Space Disease, Emergency Thoracocentesis & Chest Tube Management 4.4 Oxygen Delivery Modalities, Capnography & Mechanical Ventilation Basics

5 Chapter 5: Gastrointestinal & Hepatic Emergencies

5.1 Gastric Dilatation-Volvulus (GDV): Resuscitation, Decompression & Critical Nursing 5.2 Acute Abdomen, Septic Peritonitis & Canine Parvoviral Enteritis 5.3 Acute Pancreatitis, Acute Hemorrhagic Diarrhea Syndrome & Mesenteric Volvulus 5.4 Acute Hepatic Failure, Hepatic Encephalopathy & Biliary Emergencies

6 Chapter 6: Anesthesia, Analgesia & Constant Rate Infusions

6.1 Emergency Anesthesia Protocols & High-Risk Patient Stabilization 6.2 Multimodal Analgesia, Pain Scoring Scales & Local/Regional Anesthesia 6.3 Constant Rate Infusions (CRIs): Formulations, Calculations & Monitoring 6.4 Anesthetic Complications: Hypotension, Hypothermia & Emergency Interventions

7 Chapter 7: Renal & Urinary Emergencies

7.1 Acute Kidney Injury (AKI): Pathophysiology, IRIS Staging & Renal Replacement Therapy 7.2 Feline Urethral Obstruction: Deobstruction, Electrolyte Crises & Post-Obstructive Diuresis 7.3 Uroabdomen & Lower Urinary Tract Trauma: Diagnosis & Resuscitation

8 Chapter 8: Hemolymphatic, Transfusion Medicine & Sepsis/SIRS

8.1 Transfusion Medicine: Blood Typing, Crossmatching & Component Therapy 8.2 Immune-Mediated Hemolytic Anemia (IMHA) & Immune-Mediated Thrombocytopenia (IMTP) 8.3 Sepsis, Systemic Inflammatory Response Syndrome (SIRS) & DIC 8.4 Oncologic Emergencies: Tumor Lysis Syndrome, Bleeding Masses & Hypercalcemia

9 Chapter 9: Environmental, Toxicological, Ophthalmic & Exotic Species Emergencies

9.1 Heatstroke, Severe Hypothermia & Thermal Burn Management 9.2 Envenomation Syndromes & Acute Anaphylaxis Management 9.3 Common Small Animal Toxicities: Chocolate, Xylitol, NSAIDs & Rodenticides 9.4 Neurotoxins, Ethylene Glycol, Plant Toxins & Extracorporeal Therapies 9.5 Ophthalmologic Emergencies: Proptosis, Acute Glaucoma, Corneal Perforation & Chemical Injury 9.6 Emergency Care of Exotic Companion Species: Rabbits, Rodents, Ferrets, Birds & Reptiles

10 Chapter 10: Neurological Emergencies

10.1 Status Epilepticus & Cluster Seizures: Emergency Protocols & Refractory Therapy 10.2 Traumatic Brain Injury (TBI), Intracranial Pressure (ICP) & Modified Glasgow Coma Scale 10.3 Acute Spinal Cord Emergencies: Intervertebral Disc Disease (IVDD) & Neuro-Localization

11 Chapter 11: Endocrine & Metabolic Crises

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Acute Adrenocortical Crisis (Addisonian Crisis) & Hypoadrenocorticism 11.3 Thyroid Storm, Feline Hyperthyroid Crises & Severe Hypoglycemia

12 Chapter 12: Reproductive & Musculoskeletal Emergencies

12.1 Reproductive Emergencies: Dystocia, Pyometra & Puerperal Hypocalcemia 12.2 Musculoskeletal Trauma: Open Fractures, Luxations, Splints & Compartment Syndrome 12.3 Rhabdomyolysis, Crush Injury & Polytrauma Damage Control Resuscitation

13 Chapter 13: Advanced Critical Care Monitoring, Vascular Access & The Rule of 20

13.1 Central Venous Catheterization, Arterial Lines & Intraosseous Access 13.2 Hemodynamic Monitoring: Invasive vs. Non-Invasive Blood Pressure, CVP & Cardiac Output 13.3 Kirby's Rule of 20: Comprehensive Daily Critical Patient Evaluation Checklist

2.2 Advanced Life Support (ALS): Emergency Pharmacopeia, Reversals & Defibrillation

Key Takeaways Explain This Topic AI

Classify arrest rhythms immediately at the 2-minute mark into Shockable (Ventricular Fibrillation and Pulseless Ventricular Tachycardia) vs. Non-Shockable (Asystole and Pulseless Electrical Activity).

Administer low-dose epinephrine (0.01 mg/kg IV/IO, 1:1,000 solution at 0.01 mL/kg) or vasopressin (0.8 U/kg IV/IO) every other 2-minute cycle (every 3–5 minutes); high-dose epinephrine is removed from routine protocols due to poor neurological outcomes.

Administer rapid reversal agents when anesthetic/sedative overdose is suspected: Naloxone (0.04 mg/kg for opioids), Flumazenil (0.02 mg/kg for benzodiazepines), and Atipamezole (same volume as dexmedetomidine) for alpha-2 agonists.

Perform electrical defibrillation for shockable rhythms using biphasic waveforms at 2–4 J/kg (starting at 2 J/kg) or monophasic at 4–6 J/kg; immediately resume a 2-minute cycle of chest compressions post-shock before checking ECG rhythm.

When IV/IO access is impossible, administer NAVEL drugs (Naloxone, Atropine, Vasopressin, Epinephrine, Lidocaine) intratracheally at 2–3 times the IV dose diluted in sterile saline via a catheter passed beyond the endotracheal tube.

Last updated: August 2026

Advanced Life Support (ALS): Emergency Pharmacopeia, Reversals & Defibrillation

Core Knowledge: Advanced Life Support (ALS) builds upon uninterrupted, high-quality BLS. ALS encompasses the systematic identification of arrest rhythms, establishment of vascular or intraosseous access, administration of emergency vasopressors and reversal agents, and prompt electrical defibrillation. High-performance resuscitation teams execute ALS interventions seamlessly without interrupting 2-minute BLS compression cycles.

1. Rhythm Diagnosis: Shockable vs. Non-Shockable Pathways

At the conclusion of each 2-minute BLS cycle, compressions pause for no more than 3 to 5 seconds to evaluate the electrocardiographic (ECG) rhythm. [2-Minute BLS Cycle Ends]

  • │
  • < 5s Rhythm & Pulse Check
  • │
  • ┌──────────────────────┴──────────────────────┐
  • [SHOCKABLE] [NON-SHOCKABLE]
  • Ventricular Fibrillation (VF) • Asystole
  • Pulseless Vent. Tachycardia (pVT) • Pulseless Elec. Activity (PEA)
  • │ │
  • 1. Clear & Deliver Shock (2-4 J/kg biphasic) 1. Low-Dose Epinephrine (0.01 mg/kg)
  • 2. RESUME COMPRESSIONS IMMEDIATELY or Vasopressin (0.8 U/kg)
  • 3. Complete full 2-min cycle 2. Atropine (0.04 mg/kg) if high vagal
  • 4. Antiarrhythmics if refractory 3. Administer Reversals if indicated
  • Rhythm Definitions

Ventricular Fibrillation (VF): Chaotic, disorganized baseline without recognizable P-QRS-T complexes, representing uncoordinated, ineffective myocardial fibrillatory activity.

Pulseless Ventricular Tachycardia (pVT): Rapid, wide, and bizarre QRS complexes at rates typically >200 bpm with absent peripheral pulses and no cardiac output.

Asystole (Flatline): Complete absence of electrical and mechanical ventricular activity (ventricular standstill). Always verify lead attachment, gain settings, and switch leads before confirming.

Pulseless Electrical Activity (PEA): Presence of organized, near-normal or wide electrical waveforms on ECG in the complete absence of myocardial contraction and palpable pulses.

2. Emergency Vasopressors & Inotropes

Vasopressors induce peripheral arterial vasoconstriction, preventing peripheral vascular collapse and shunting available blood volume to the central circulation, thereby boosting Coronary Perfusion Pressure (CPP) and Cerebral Perfusion Pressure .

Epinephrine (Adrenaline)

Mechanism: Potent endogenous catecholamine stimulating α 1 \alpha_1 α 1 ​ , β 1 \beta_1 β 1 ​ , and β 2 \beta_2 β 2 ​ adrenergic receptors. The therapeutic benefit during CPR is driven almost exclusively by α 1 \alpha_1 α 1 ​ -mediated peripheral arterial vasoconstriction .

Low-Dose Epinephrine Protocol (Standard of Care):

Dose: 0.01 mg/kg IV or IO (equivalent to 0.01 mL/kg of 1:1,000 [1 mg/mL] solution, or 0.1 mL/kg of 1:10,000 [0.1 mg/mL] solution).

Frequency: Administered every other 2-minute cycle (every 3 to 5 minutes) in non-shockable rhythms (asystole and PEA).

High-Dose Epinephrine (0.1 mg/kg): RECOVER guidelines specifically remove high-dose epinephrine from routine resuscitation algorithms . Clinical trials demonstrate that while high-dose epinephrine may transiently increase initial ROSC rates, it causes profound post-resuscitation myocardial dysfunction, severe cerebral ischemia, malignant arrhythmias, and significantly worsens survival to hospital discharge. It is reserved only for prolonged, refractory CPR (>10–15 minutes) at clinician discretion.

Vasopressin (Antidiuretic Hormone)

Mechanism: Stimulates vascular V 1 V_1 V 1 ​ receptors on vascular smooth muscle, causing profound peripheral vasoconstriction through non-adrenergic pathways.

Dose: 0.8 U/kg IV or IO .

Key Clinical Advantage: Unlike catecholamines (epinephrine), vasopressin remains fully active in severe acidemia and hypoxemia , where adrenergic receptors are desensitized. It does not stimulate cardiac β 1 \beta_1 β 1 ​ receptors, avoiding increases in myocardial oxygen consumption. Can be used in place of, or alternated with, low-dose epinephrine.

3. Parasympatholytics: Atropine

Mechanism: Competitive muscarinic acetylcholine receptor antagonist that blocks parasympathetic vagal input to the sinoatrial (SA) and atrioventricular (AV) nodes.

Dose: 0.04 mg/kg IV or IO .

Clinical Indications: Indicated in CPA driven by high vagal tone (e.g., gastrointestinal disease, respiratory tract obstruction, ocular surgery, neurological disease, or severe sinus bradycardia degenerating into asystole/PEA). RECOVER recommends administration during the first cycle of asystole/PEA.

4. Antidotes & Anesthetic Reversal Agents

If the patient arrested following the administration of sedatives, opioids, or anesthetics, specific competitive antagonists must be administered immediately during ALS:

Drug Class / Agonist Specific Antagonist Dose & Route Clinical Notes

Opioids (Fentanyl, Hydromorphone, Morphine, Methadone) Naloxone 0.04 mg/kg IV/IO/IT Pure competitive μ \mu μ , κ \kappa κ , δ \delta δ antagonist. Reverses opioid-induced respiratory depression and bradycardia.

Benzodiazepines (Midazolam, Diazepam) Flumazenil 0.02 mg/kg IV/IO Competitive GABA-receptor antagonist. Highly specific with rapid onset.

α 2 \alpha_2 α 2 ​ -Adrenergic Agonists (Dexmedetomidine, Xylazine) Atipamezole Equal volume to dexmedetomidine (or 5:1 weight ratio; 0.2 mg/kg IV/IM) Potent α 2 \alpha_2 α 2 ​ blocker; IV administration recommended in arrest to rapidly reverse severe peripheral vasoconstriction and bradycardia.

5. Electrical Defibrillation Mechanics & Safety

Defibrillation is the definitive and sole curative therapy for shockable rhythms (VF and pulseless VT). The electrical current depolarizes a critical mass of chaotic myocardium simultaneously, rendering the cells refractory so that the primary pacemaker (SA node) can resume coordinated pacing.

Energy Dosing Guidelines

Biphasic Defibrillator (Preferred): Delivers current bidirectionally, requiring lower energy and causing less myocardial damage.

Initial Shock Dose: 2 to 4 J/kg (start at 2 J/kg; escalate to 4 J/kg if VF persists on subsequent cycles).

Monophasic Defibrillator: Delivers current in a single direction.

Initial Shock Dose: 4 to 6 J/kg .

The Strict Post-Shock Rule Deliver Shock ⟶ IMMEDIATELY RESUME COMPRESSIONS (2 min) ⟶ Check ECG at Cycle End \text{Deliver Shock} \longrightarrow \text{IMMEDIATELY RESUME COMPRESSIONS (2 min)} \longrightarrow \text{Check ECG at Cycle End} Deliver Shock ⟶ IMMEDIATELY RESUME COMPRESSIONS (2 min) ⟶ Check ECG at Cycle End

VTS Critical Concept: Never check the ECG or palpate pulses immediately after delivering a shock! Defibrillation rarely results in an immediate organized, perfusing rhythm; instead, the stunned myocardium requires several minutes of continuous perfusion generated by BLS compressions to restore intracellular ATP and coordinated mechanical contraction. Halting compressions to view the monitor post-shock induces severe myocardial ischemia.

Antiarrhythmic Therapy for Refractory VF / Pulseless VT

When VF or pulseless VT persists despite ≥ 2 \ge 2 ≥ 2 electrical shocks:

Amiodarone: Class III antiarrhythmic (prolongs action potential and refractory period). Dose: 5 mg/kg slow IV/IO . First-line antiarrhythmic for refractory VF in dogs and cats.

Lidocaine: Class IB antiarrhythmic. Dose: 2 to 8 mg/kg IV/IO (Dogs only; caution/avoid in cats). Second-line agent when amiodarone is unavailable.

6. Routes of Emergency Drug Administration

Route Efficacy & Priority Administration Guidelines

Intravenous (IV) 1st Choice (Central or Peripheral) Flush peripheral IV injections with 5 to 10 mL of sterile saline and elevate the limb for 10–15 seconds to facilitate central venous transit.

Intraosseous (IO) 1st Alternative to IV Rapid access in pediatric, hypovolemic, or collapsed patients. Sites: Trochanteric fossa of the femur , Tibial crest , Greater tubercle of the humerus . Same doses and absorption pharmacokinetics as IV.

Intratracheal (IT) Emergency Route (Last Resort) Administer NAVEL drugs only. Dose: 2 to 3 times the IV dose , diluted in 1–5 mL of sterile saline, delivered via a long catheter passed beyond the tip of the endotracheal tube , followed by 2–3 rapid PPV breaths.

Loading diagram... RECOVER Advanced Life Support (ALS) Algorithm